Teaching an old dog new tricks: re-engineering IL-2 for immuno-oncology applications
Various approaches are being explored to address the unmet medical need among patients with advanced cancer who do not respond to immune checkpoint inhibitors. Interleukin-2 has become a prominent focus of preclinical and clinical investigation, because of its known clinical activity, the important...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-01-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/11/1/e006346.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832582826293198848 |
|---|---|
| author | Mario Sznol Naiyer Rizvi |
| author_facet | Mario Sznol Naiyer Rizvi |
| author_sort | Mario Sznol |
| collection | DOAJ |
| description | Various approaches are being explored to address the unmet medical need among patients with advanced cancer who do not respond to immune checkpoint inhibitors. Interleukin-2 has become a prominent focus of preclinical and clinical investigation, because of its known clinical activity, the important role of this cytokine in immune biology, and the ability to engineer variant proteins with potentially improved antitumor immunomodulatory activity and reduced toxicity. Bempegaldesleukin, the first of the modified IL-2 agents to reach phase 3 evaluation in combination with an anti-PD-1, did not improve outcome for patients with metastatic melanoma and renal carcinoma. The disappointing data raise important questions about the potential efficacy of other interleukin-2 variants, however, several of the other variants appear to be sufficiently differentiated in anticipated pharmacokinetic properties and immune modulatory effects to warrant continued clinical development. |
| format | Article |
| id | doaj-art-a65296e3368d4716886c59a747826372 |
| institution | Kabale University |
| issn | 2051-1426 |
| language | English |
| publishDate | 2023-01-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-a65296e3368d4716886c59a7478263722025-01-29T09:10:15ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262023-01-0111110.1136/jitc-2022-006346Teaching an old dog new tricks: re-engineering IL-2 for immuno-oncology applicationsMario Sznol0Naiyer Rizvi14Yale University Department of Medical Oncology: Yale Cancer Center, New Haven, CT, USAThoracic Oncology, Columbia University Irving Medical Center, New York, New York, USAVarious approaches are being explored to address the unmet medical need among patients with advanced cancer who do not respond to immune checkpoint inhibitors. Interleukin-2 has become a prominent focus of preclinical and clinical investigation, because of its known clinical activity, the important role of this cytokine in immune biology, and the ability to engineer variant proteins with potentially improved antitumor immunomodulatory activity and reduced toxicity. Bempegaldesleukin, the first of the modified IL-2 agents to reach phase 3 evaluation in combination with an anti-PD-1, did not improve outcome for patients with metastatic melanoma and renal carcinoma. The disappointing data raise important questions about the potential efficacy of other interleukin-2 variants, however, several of the other variants appear to be sufficiently differentiated in anticipated pharmacokinetic properties and immune modulatory effects to warrant continued clinical development.https://jitc.bmj.com/content/11/1/e006346.full |
| spellingShingle | Mario Sznol Naiyer Rizvi Teaching an old dog new tricks: re-engineering IL-2 for immuno-oncology applications Journal for ImmunoTherapy of Cancer |
| title | Teaching an old dog new tricks: re-engineering IL-2 for immuno-oncology applications |
| title_full | Teaching an old dog new tricks: re-engineering IL-2 for immuno-oncology applications |
| title_fullStr | Teaching an old dog new tricks: re-engineering IL-2 for immuno-oncology applications |
| title_full_unstemmed | Teaching an old dog new tricks: re-engineering IL-2 for immuno-oncology applications |
| title_short | Teaching an old dog new tricks: re-engineering IL-2 for immuno-oncology applications |
| title_sort | teaching an old dog new tricks re engineering il 2 for immuno oncology applications |
| url | https://jitc.bmj.com/content/11/1/e006346.full |
| work_keys_str_mv | AT mariosznol teachinganolddognewtricksreengineeringil2forimmunooncologyapplications AT naiyerrizvi teachinganolddognewtricksreengineeringil2forimmunooncologyapplications |